Pulling SEC filings + quote and writing the call…

ANI PHARMACEUTICALS INC
Next earnings Aug 6, 2026 · consensus $2.05 EPS, $267M rev
Last earnings -2.4% on 2026-05-08
Revenue grew 43.8% YoY.
Middling fundamentals offset by an attractive price (~49% below fair value) — worth a look on the value angle.
Sources: SEC EDGAR (CIK 0001023024, latest 10-Q filed 2026-05-08) · EODHD · as of 6/26/2026, 7:09:35 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
ANI PHARMACEUTICALS INC shows $883M in FY2025 revenue (+43.8% YoY), a 8.9% net margin, and 14.5% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $216M | $316M | $487M | $614M | $883M |
| Gross profit | — | — | — | — | — |
| Operating income | -$39.8M | -$35.3M | $47.0M | $584K | $111M |
| Net income | -$42.6M | -$47.9M | $18.8M | -$18.5M | $78.3M |
| Diluted EPS | -$3.40 | -$3.05 | $0.85 | -$1.04 | $3.32 |
| Net margin | -19.7% | -15.1% | 3.9% | -3.0% | 8.9% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1049 tracked peers · median
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Last 90 days: 0 open-market buys · 5 sales
| 2026-06-12 | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | Sell | 500.00 @ $82.03 | $41.0K |
| 2026-06-08 | HAUGHEY THOMAS Director | Sell | 2.00K @ $80.88 | $162K |
| 2026-06-05 | CAREY STEPHEN P. SVP & CFO | Exercise | 3.31K @ $49.51 | $164K |
| 2026-06-05 | CAREY STEPHEN P. SVP & CFO | Sell | 3.31K @ $80.00 | $265K |
| 2026-05-21 | Thoma Jeanne Director | Award | 4.36K | |
| 2026-05-21 | TANNENBAUM RENEE P Director | Award | 4.36K | |
| 2026-05-21 | Pera Antonio R Director | Award | 4.36K | |
| 2026-05-21 | Leonard Matthew J Director | Award | 4.36K | |
| 2026-05-21 | HAUGHEY THOMAS Director | Award | 4.36K | |
| 2026-05-13 | Walsh Patrick D Director | Sell | 10.0K @ $80.63 | $806K |
| 2026-05-11 | Walsh Patrick D Director | Sell | 3.97K @ $80.75 | $321K |
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.